Navidea Biopharmaceuticals, Inc (NAVB)
-NYSE MKT | Prev Close: | 2.64 |
|---|
| Open: | N/A |
|---|
| Bid: | 2.37 x 500 |
|---|
| Ask: | 3.48 x 200 |
|---|
| 1y Target Est: | 5.22 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | 4-Nov-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 2.14 - 3.59 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 633,280 |
|---|
| Market Cap: | 314.00M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Does Navidea's Recent Offering Make It A Buy Or Sell?at Seeking Alpha(Mon, Sep 30)
- 2 More Bold Speculative Biotech Playsat Seeking Alpha(Sun, Sep 29)
- Navidea Biopharmaceuticals to Present at BioCentury’s NewsMakers in the Biotech Industry ConferenceBusiness Wire(Tue, Sep 24)
- NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial StatementsEDGAR Online(Tue, Sep 24)
- Navidea sees net proceeds of $28.8M from registered direct offering of stocktheflyonthewall.com(Tue, Sep 24)
- Navidea Biopharmaceuticals Completes $30 Million Registered Direct Offering of Common StockBusiness Wire(Tue, Sep 24)
- Independent Investigators Report Lymphoseek® Results in JAMA Otolaryngology Head and Neck SurgeryBusiness Wire(Thu, Sep 19)
- Navidea Biopharmaceuticals Presents New Data on Precision Diagnostic Platform at Harvard ConferenceBusiness Wire(Thu, Sep 19)
- Here's What This $58 Billion Hedge Fund Company Is Buyingat Motley Fool(Wed, Sep 18)
- NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial StatementsEDGAR Online(Thu, Sep 12)
- NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, FinancEDGAR Online(Thu, Sep 5)
- Navidea Awarded an Additional NIH SBIR Grant for NAV4694 Beta-Amyloid Imaging Agent for Study in Mild Cognitive ImpairmentBusiness Wire(Wed, Sep 4)
- Navidea - Worth A Look?at Seeking Alpha(Wed, Sep 4)
- 3 Companies With High Short Interest And Improving Outlooksat Seeking Alpha(Mon, Aug 26)
- 4 Healthcare Stock Stories To Cure Thursday’s Investment Illsat Wall St. Cheat Sheet(Thu, Aug 22)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 1,553.79 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.29 |
|---|
| Quarterly EPS Est
(Sep-13)
: | -0.08 |
|---|
| Mean Recommendation*: | 1.9 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision diagnostics and radiopharmaceutical agents.
View More